Graphite Bio (NASDAQ: GRPH)
Some price data may be temporarily unavailable.
Graphite Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Graphite Bio Company Info
Graphite Bio, Inc. operates as a clinical-stage gene editing company. It focuses on therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA.
News & Analysis
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.